Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
Status: | Completed |
---|---|
Conditions: | Other Indications, Blood Cancer, Hematology |
Therapuetic Areas: | Hematology, Oncology, Other |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | March 2006 |
End Date: | July 2015 |
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
This is an open-label, continuous daily dosing, two-part safety and efficacy study of
SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+). Part 1 is a
dose-escalation study in chronic phase Chronic Myelogenous Leukemia (CML) subjects to
establish the maximum tolerated dose (MTD) in this subject population. Part 2 has begun
after the completion of Part 1 and after a dose has been established for the compound in
chronic phase subjects. Part 2 is a study of the the efficacy of 500mg daily oral SKI-606
(bosutinib) in patients with all phases of Ph+ CML and Ph+ Acute Lymphocytic Leukemia (ALL).
The protocol will test the hypotheses that oral daily dosing of bosutinib at 500 mg will
attain (1) Major Cytogenetic Response (MCyR) in chronic phase CML patients and (2) Overall
Hematological Response (OHR) in advanced leukemia patients. Each phase of the disease will
be evaluated as a separate cohort.
SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+). Part 1 is a
dose-escalation study in chronic phase Chronic Myelogenous Leukemia (CML) subjects to
establish the maximum tolerated dose (MTD) in this subject population. Part 2 has begun
after the completion of Part 1 and after a dose has been established for the compound in
chronic phase subjects. Part 2 is a study of the the efficacy of 500mg daily oral SKI-606
(bosutinib) in patients with all phases of Ph+ CML and Ph+ Acute Lymphocytic Leukemia (ALL).
The protocol will test the hypotheses that oral daily dosing of bosutinib at 500 mg will
attain (1) Major Cytogenetic Response (MCyR) in chronic phase CML patients and (2) Overall
Hematological Response (OHR) in advanced leukemia patients. Each phase of the disease will
be evaluated as a separate cohort.
Inclusion Criteria:
- Ph+ CML or Ph+ ALL who are primarily refractory to full-dose imatinib (600 mg), have
disease progression/relapse while on full-dose imatinib, or are intolerant of any
dose of imatinib.
- At least 3 months post stem cell transplantation
- Able to take daily oral capsules/tablets reliably
Exclusion Criteria:
- Subjects with Philadelphia chromosome, and bcr-abl negative CML
- Overt leptomeningeal leukemia
- Subjects without evidence of leukemia in bone marrow (extramedullary disease only)
We found this trial at
35
sites
3800 Reservoir Rd NW
Washington, District of Columbia 20007
Washington, District of Columbia 20007
(202) 687-7695
Georgetown University Medical Center Georgetown University Medical Center is committed to excellence in research, education...
Click here to add this to my saved trials
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
Click here to add this to my saved trials
Emory University Hospital As the largest health care system in Georgia and the only health...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
Click here to add this to my saved trials
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
Duarte, California 91010
626-256-HOPE (4673)
City of Hope National Medical Center City of Hope is dedicated to making a difference...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Indianapolis, Indiana 46237
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Rochester, New York 14642
Click here to add this to my saved trials
Click here to add this to my saved trials
Shreveport, Louisiana 71130
Click here to add this to my saved trials
Click here to add this to my saved trials
3800 Reservoir Rd NW
Washington, District of Columbia 20007
Washington, District of Columbia 20007
(202) 444-2000
Georgetown University Hospital MedStar Georgetown University Hospital is a not-for-profit, acute-care teaching and research hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Washington, District of Columbia 20037
Click here to add this to my saved trials